OWONIKOKO, T. K.; PAPADOPOULOS, K. P.; JOHNSON, M. L.; AL., E. Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data. SKIN The Journal of Cutaneous Medicine, v. 2, p. S78, 17 Dec. 2018.